Llwytho...
CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA
BACKGROUND: Benefit from temozolomide chemotherapy in glioblastoma is essentially limited to patients with tumors that exhibit O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation. Recent retrospective clinical analyses indicate that the impact of the MGMT status on chemosensitivity...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Neuro Oncol |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Oxford University Press
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216676/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.193 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|